Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Romain Ragonnet

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
The Lancet. Infectious Diseases|July 7, 2018
Appropriate comparisons of tuberculosis latency structures with empiric dataJames M Trauer, Romain Ragonnet, Emma S McBryde
The Lancet. Global Health|September 21, 2019
Modelling tuberculosis control priorities: more of the same will not doChristian Wejse, Romain Ragonnet, Emma S McBryde, et al.
BMC Infectious Diseases|August 9, 2017
Modular programming for tuberculosis control, the "AuTuMN" platformJames McCracken Trauer, Romain Ragonnet, Tan Nhut Doan, et al.
BMC Medicine|November 23, 2019
Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countriesRomain Ragonnet, James M Trauer, Nicholas Geard, et al.
Journal of Medical Ethics|June 1, 2021
Ethics of selective restriction of liberty in a pandemicJames Cameron, Bridget Williams, Romain Ragonnet, et al.
Tropical Medicine and Infectious Disease|April 27, 2019
Strategic Planning for Tuberculosis Control in the Republic of FijiRomain Ragonnet, Frank Underwood, Tan Doan, et al.
The Medical Journal of Australia|December 9, 2020
Time for a clear national COVID-19 strategyJames M Trauer, Ben J Marais, Romain Ragonnet, et al.
BMC Infectious Diseases|January 25, 2022
Estimating tuberculosis drug resistance amplification rates in high-burden settingsMalancha Karmakar, Romain Ragonnet, David B Ascher, et al.
American Journal of Epidemiology|May 21, 2016
Scenario Analysis for Programmatic Tuberculosis Control in Western Province, Papua New GuineaJames M Trauer, Justin T Denholm, Saba Waseem, et al.
BMC Infectious Diseases|January 8, 2017
High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?Romain Ragonnet, James M Trauer, Justin T Denholm, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
The Lancet. Infectious Diseases|July 7, 2018
Appropriate comparisons of tuberculosis latency structures with empiric dataJames M Trauer, Romain Ragonnet, Emma S McBryde
The Lancet. Global Health|September 21, 2019
Modelling tuberculosis control priorities: more of the same will not doChristian Wejse, Romain Ragonnet, Emma S McBryde, et al.
BMC Infectious Diseases|August 9, 2017
Modular programming for tuberculosis control, the "AuTuMN" platformJames McCracken Trauer, Romain Ragonnet, Tan Nhut Doan, et al.
BMC Medicine|November 23, 2019
Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countriesRomain Ragonnet, James M Trauer, Nicholas Geard, et al.
Journal of Medical Ethics|June 1, 2021
Ethics of selective restriction of liberty in a pandemicJames Cameron, Bridget Williams, Romain Ragonnet, et al.
Tropical Medicine and Infectious Disease|April 27, 2019
Strategic Planning for Tuberculosis Control in the Republic of FijiRomain Ragonnet, Frank Underwood, Tan Doan, et al.
The Medical Journal of Australia|December 9, 2020
Time for a clear national COVID-19 strategyJames M Trauer, Ben J Marais, Romain Ragonnet, et al.
BMC Infectious Diseases|January 25, 2022
Estimating tuberculosis drug resistance amplification rates in high-burden settingsMalancha Karmakar, Romain Ragonnet, David B Ascher, et al.
American Journal of Epidemiology|May 21, 2016
Scenario Analysis for Programmatic Tuberculosis Control in Western Province, Papua New GuineaJames M Trauer, Justin T Denholm, Saba Waseem, et al.
BMC Infectious Diseases|January 8, 2017
High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?Romain Ragonnet, James M Trauer, Justin T Denholm, et al.
Pageof 4